Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 2;10(6):e112290.
doi: 10.5812/aapm.112290. eCollection 2020 Dec.

Utilization of Intravenous Lidocaine Infusion for the Treatment of Refractory Chronic Pain

Janell Tully  1 , Jai Won Jung  2 , Anjana Patel  2 , Alyson Tukan  1 , Sameer Kandula  1 , Allen Doan  1 , Farnad Imani  3 , Giustino Varrassi  4 , Elyse M Cornett  5 , Alan David Kaye  5 , Omar Viswanath  5   6   7   8 , Ivan Urits  5   9
Affiliations
Review

Utilization of Intravenous Lidocaine Infusion for the Treatment of Refractory Chronic Pain

Janell Tully et al. Anesth Pain Med. .

Abstract

Context: Chronic pain accounts for one of the most common reasons patients seek medical care. The financial burden of chronic pain on health care is seen by direct financial cost and resource utilization. Many risk factors may contribute to chronic pain, but there is no definite risk. Managing chronic pain is a balance between maximally alleviating symptoms by utilizing a therapeutic regimen that is safe for long-term use. Currently, non-opioid analgesics, NSAIDs, and opioids are some of the medical treatment options, but these have numerous adverse effects and may not be the best option for long-term use. However, Lidocaine can achieve both central and peripheral analgesic effects with relatively few side effects, which may be an ideal compound for managing chronic pain.

Evidence acquisition: This is a Narrative Review.

Results: Infusion of lidocaine (2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide), an amino-amide compound, is emerging as a promising option to fill the therapeutic void for treatment of chronic pain. Numerous studies have outlined dosing protocols for lidocaine infusion for the management of perioperative pain, outlined below. While there are slight variations in these different protocols, they all center around a similar dosing regimen to administer a bolus to reach a rapid steady state, followed by infusion for up to 72 hours to maintain the therapeutic analgesic effects.

Conclusions: Lidocaine may be a promising pharmacologic solution with a low side effect profile that provides central and peripheral analgesia. Even though the multifaceted mechanism is not entirely understood yet, lidocaine may be a promising novel remedy in treating chronic pain in various conditions.

Keywords: CRPS; Chronic Pain; Fibromyalgia; Headache; Lidocaine; Low Back Pain.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests: None declared.

References

    1. Kandil E, Melikman E, Adinoff B. Lidocaine Infusion: A Promising Therapeutic Approach for Chronic Pain. J Anesth Clin Res. 2017;8(1) doi: 10.4172/2155-6148.1000697. - DOI - PMC - PubMed
    1. Chapman CR, Vierck CJ. The Transition of Acute Postoperative Pain to Chronic Pain: An Integrative Overview of Research on Mechanisms. J Pain. 2017;18(4):359 e1–359 e38. doi: 10.1016/j.jpain.2016.11.004. - DOI - PubMed
    1. Woolf CJ, American College of P, American Physiological S. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140(6):441–51. doi: 10.7326/0003-4819-140-8-200404200-00010. - DOI - PubMed
    1. Fornasari D. Pain Mechanisms in Patients with Chronic Pain. Clin Drug Investig. 2012;32:45–52. doi: 10.2165/11630070-000000000-00000. - DOI - PubMed
    1. Aronoff GM. What Do We Know About the Pathophysiology of Chronic Pain? Implications for Treatment Considerations. Med Clin North Am. 2016;100(1):31–42. doi: 10.1016/j.mcna.2015.08.004. - DOI - PubMed

LinkOut - more resources